Increased risk of gastrointestinal malignancy in patients with diabetes mellitus and correlations with Anti-Diabetes drugs: A nationwide population-based study in Taiwan

Internal Medicine

Volumn 52, Issue 9, 2013, Pages 939-946

  Chiu, Chun Chih ^a,b   Huang, Chin Chou ^a,b   Chen, Yu Chun ^a   Chen, Tzeng Ji ^a,b   Liang, Ying ^a   Lin, Shing Jong ^a,b   Chen, Jaw Wen ^a,b   Leu, Hsin Bang ^a,b   Chan, Wan Leong ^a  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Diabetes mellitus; Gastrointestinal malignancy

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE; INSULIN; MEGLITINIDE; SULFONYLUREA; ALPHA GLUCOSIDASE; ANTIDIABETIC AGENT; BIGUANIDE DERIVATIVE; SULFONYLUREA DERIVATIVE;

ADULT; ARTICLE; CANCER RISK; COHORT ANALYSIS; COLON CANCER; CONTROLLED STUDY; DIABETES MELLITUS; DIGESTIVE SYSTEM CANCER; DISEASE ASSOCIATION; ESOPHAGUS CANCER; FEMALE; FOLLOW UP; GASTROINTESTINAL TUMOR; HUMAN; INCIDENCE; LIVER CANCER; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PANCREAS CANCER; RECTUM CANCER; SMALL INTESTINE CANCER; STOMACH CANCER; TAIWAN; CHEMICALLY INDUCED; CLASSIFICATION; DIGESTIVE SYSTEM NEOPLASMS; LIVER NEOPLASMS; PANCREATIC NEOPLASMS; PROPORTIONAL HAZARDS MODEL;

ALPHA-GLUCOSIDASES; BIGUANIDES; COHORT STUDIES; DIABETES MELLITUS; DIGESTIVE SYSTEM NEOPLASMS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LIVER NEOPLASMS; PANCREATIC NEOPLASMS; PROPORTIONAL HAZARDS MODELS; SAMPLING STUDIES; SULFONYLUREA COMPOUNDS; TAIWAN; THIAZOLIDINEDIONES;

EID: 84877100258     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.52.8276     Document Type: Article

References (45)

1. Stovring H, Andersen M, Beck-Nielsen H, Green A, Vach W. Rising prevalence of diabetes: evidence from a Danish pharmacoepidemiological database. Lancet 362: 537-538, 2003.
2. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 414: 782-787, 2001.
3. La Vecchia C, Negri E, Franceschi S, D'Avanzo B, Boyle P. A case-control study of diabetes mellitus and cancer risk. Br J Cancer 70: 950-953, 1994.
4. Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA 273: 1605-1609, 1995.
5. Renehan A, Smith U, Kirkman MS. Linking diabetes and cancer: a consensus on complexity. Lancet 375: 2201-2202, 2010.
6. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care 33: 1674-1685, 2010.
7. Campbell PT, Deka A, Jacobs EJ, et al. Prospective study reveals associations between colorectal cancer and type 2 diabetes mellitus or insulin use in men. Gastroenterology 139: 1138-1146, 2010.
8. Chen HF, Chen P, Li CY. Risk of malignant neoplasm of the pancreas in relation to diabetes: a population-based study in Taiwan. Diabetes Care 34: 1177-1179, 2011.
9. Liao KF, Lai SW, Li CI, Chen WC. Diabetes mellitus correlates with increased risk of pancreatic cancer: a population-based cohort study in Taiwan. J Gastroenterol Hepatol 27: 709-713, 2012.
10. Ben Q, Xu M, Ning X, et al. Diabetes mellitus and risk of pancreatic cancer: a meta-analysis of cohort studies. Eur J Cancer 47: 1928-1937, 2011.
11. El-Serag HB, Richardson PA, Everhart JE. The role of diabetes in hepatocellular carcinoma: a case-control study among United States Veterans. Am J Gastroenterol 96: 2462-2467, 2001.
12. Lee MS, Hsu CC, Wahlqvist ML, Tsai HN, Chang YH, Huang YC. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer 11: 20, 2011.
13. Hemkens LG, Grouven U, Bender R, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 52: 1732-1744, 2009.
14. Monami M, Lamanna C, Marchionni N, Mannucci E. Rosiglitazone and risk of cancer: a meta-analysis of randomized clinical trials. Diabetes Care 31: 1455-1460, 2008.
15. Pocock SJ, Smeeth L. Insulin glargine and malignancy: an unwarranted alarm. Lancet 374: 511-513, 2009.
16. Chang CH, Toh S, Lin JW, et al. Cancer risk associated with insulin glargine among adult type 2 diabetes patients: a nationwide cohort study. PLoS One 6: e21368, 2011.
17. Lai SW, Liao KF, Chen PC, Tsai PY, Hsieh DP, Chen CC. Antidiabetes drugs correlate with decreased risk of lung cancer: a population-based observation in Taiwan. Clin Lung Cancer 13: 143-148, 2012.
18. Chang CH, Lin JW, Wu LC, Lai MS, Chuang LM, Chan KA. Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus. Hepatology 55: 1462-1472, 2012.
19. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52: 1766-1777, 2009.
20. Cheng TM. Taiwan's new national health insurance program: genesis and experience so far. Health Aff (Millwood) 22: 61-76, 2003.
21. Huang CC, Chen YC, Leu HB, et al. Risk of adverse outcomes in Taiwan associated with concomitant use of clopidogrel and proton pump inhibitors in patients who received percutaneous coronary intervention. Am J Cardiol 105: 1705-1709,
22. Huang CC, Chan WL, Chen YC, et al. Statin use in patients with asthma: a nationwide population-based study. Eur J Clin Invest 41: 507-512, 2011.
23. Huang CC, Chan WL, Chen YC, et al. Angiotensin II receptor blockers and risk of cancer in patients with systemic hypertension. Am J Cardiol 107: 1028-1033, 2011.
24. Chiu CC, Huang CC, Chan WL, et al. Increased risk of ischemic stroke in patients with systemic lupus erythematosus: a nationwide population-based study. Intern Med 51: 17-21, 2012.
25. Noto H, Osame K, Sasazuki T, Noda M. Substantially increased risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis of epidemiologic evidence in Japan. J Diabetes Complications 24: 345-353, 2010.
26. Ren HB, Yu T, Liu C, Li YQ. Diabetes mellitus and increased risk of biliary tract cancer: systematic review and meta-analysis. Cancer Causes Control 22: 837-847, 2011.
27. Baur DM, Klotsche J, Hamnvik OP, et al. Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort. Metabolism 60: 1363-1371, 2011.
28. Jamal MM, Yoon EJ, Vega KJ, Hashemzadeh M, Chang KJ. Diabetes mellitus as a risk factor for gastrointestinal cancer among American veterans. World J Gastroenterol 15: 5274-5278, 2009.
29. Heuson JC, Legros N. Influence of insulin deprivation on growth of the 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in rats subjected to alloxan diabetes and food restriction. Cancer Res 32: 226-232, 1972.
30. Macaulay VM. Insulin-like growth factors and cancer. Br J Cancer 65: 311-320, 1992.
31. Giovannucci E. Insulin and colon cancer. Cancer Causes Control 6: 164-179, 1995.
32. Açbay O, Celik AF, Gündo-du S. Does Helicobacter pyloriinduced gastritis enhance food-stimulated insulin release? Dig Dis Sci 41: 1327-1331, 1996.
33. Guo X, Zhao BH, Zhang MX. Risk factors of Helicobacter pylori infection among adults in northern China. Hepatogastroenterology 58: 306-310, 2011.
34. Shintani Y, Fujie H, Miyoshi H, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 126: 840-848, 2004.
35. Straus DS. Growth-stimulatory actions of insulin in vitro and in vivo. Endocr Rev 5: 356-369, 1984.
36. Tsakraklides VG, Blieden LC, Edwards JE. Coronary atherosclerosis and myocardial infarction associated with systemic lupus erythematosus. Am Heart J 87: 637-641, 1974.
37. Clemmons DR, Maile LA, Ling Y, Yarber J, Busby WH. Role of the integrin αVβ3 in mediating increased smooth muscle cell responsiveness to IGF-I in response to hyperglycemic stress. Growth Horm IGF Res 17: 265-270, 2007.
38. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 330: 1304-1305, 2005.
39. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 32: 1620-1625, 2009.
40. Landman GW, Kleefstra N, van Hateren KJ, Groenier KH, Gans RO, Bilo HJ. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care 33: 322-326, 2010.
41. Yang YX. Do diabetes drugs modify the risk of pancreatic cancer? Gastroenterology 137: 412-415, 2009.
42. Galli A, Ceni E, Mello T, et al. Thiazolidinediones inhibit hepatocarcinogenesis in hepatitis B virus-transgenic mice by peroxisome proliferator-activated receptor γ-independent regulation of nucleophosmin. Hepatology 52: 493-505, 2010.
43. Takano S, Kubota T, Nishibori H, et al. Pioglitazone, a ligand for peroxisome proliferator-activated receptor-γ acts as an inhibitor of colon cancer liver metastasis. Anticancer Res 28: 3593-3599, 2008.
44. Kim DM, Won M, Chung CS, et al. JNK-mediated transcriptional upregulation of RhoB is critical for apoptosis of HCT-116 colon cancer cells by a novel diarylsulfonylurea derivative. Apoptosis 15: 1540-1548, 2010.
45. Seshasai SR, Kaptoge S, Thompson A, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 364: 829-841, 2011.